Cancer Family
Urinary System Neoplasm
CI-CAN-00000379Explore in graph →
Non-malignant964 active trials28 approved drugs109 evidence items
- NCIt
- C3431
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000379Explore in graph →
Clinical trials
4,238 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04262427 | The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell Carcinoma(CAPER) | unknown | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | Aug 23, 2022 | clinicaltrials |
| NCT05440045 | A Clinical Study of 6MW3211 in Patients With Renal Cancer | unknown | Phase 2 | 30 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 0 | Aug 17, 2022 |
| clinicaltrials |
| NCT05243173 | Biomarkers of Response to Systemic Treatments in FH-deficient RCC | unknown | — | 100 | RenJi HospitalOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT05503563 | A Proposed Tetra-modal Treatment Protocol for Muscle Invasive Urothelial Carcinoma of the Urinary Bladder | unknown | — | 50 | Assiut UniversityOTHER | 1 | Aug 16, 2022 | clinicaltrials |
| NCT03844256 | A Study of Mitomycin-c/ Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study(CRIMI) | unknown | Phase 1 / Phase 2 | 50 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 12, 2022 | clinicaltrials |
| NCT03934827 | MRx0518 in Patients With Solid Tumours Waiting Surgical Removal of the Tumour(MICROBIOME) | unknown | Phase 1 | 120 | Imperial College LondonOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT04282876 | Influence of Hormone Treatment in Radiation Therapy for Bladder Cancer | unknown | — | 60 | Aarhus University HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05485883 | Tislelizumab Plus Lenvatinib in Stage III-IV RCC(TILUR) | unknown | Phase 2 | 20 | Tianjin Medical University Second HospitalOTHER | 1 | Aug 8, 2022 | clinicaltrials |
| NCT05486871 | Oncological and Functional Outcomes of Laparoscopic Partial Nephrectomy in Renal Cell Carcinoma Stages T1 Versus T2a: Prospective Comparative Study. | unknown | N/A | 30 | Sohag UniversityOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT05488353 | A Clinical Study of Disitamab Vedotin for Injection Combined With Penpulimab Injection in Neoadjuvant Therapy for Patients With HER2-expressing Cisplatin-intolerant cT2-T4aNxM0 Bladder Urothelial Carcinoma | unknown | Phase 4 | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 4, 2022 | clinicaltrials |
| NCT05139134 | Immunohistochemical Expression of CXCL5 as a Valuable Prognostic Marker in Urinary Bladder Urothelial Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Jul 29, 2022 | clinicaltrials |
| NCT05467267 | Personalized Urine Biomarker for Patients With Bladder Cancer | unknown | — | 20 | Ziv HospitalOTHER_GOV | 0 | Jul 20, 2022 | clinicaltrials |
| NCT04839029 | Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BT | unknown | N/A | 200 | Benha UniversityOTHER | 1 | Jul 19, 2022 | clinicaltrials |
| NCT03827837 | Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors | unknown | Phase 2 | 265 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 1, 2022 | clinicaltrials |
| NCT05429710 | SOX2 & PDL1 Expression on Urinary Bladder Carcinoma | unknown | — | 60 | Sohag UniversityOTHER | 0 | Jun 23, 2022 | clinicaltrials |
| NCT05426317 | Exploratory Interventional Study of Prognostic Serum Biomarkers of Cancer Progression(Onco-PDL1s/B2M) | unknown | N/A | 100 | University Hospital, Clermont-FerrandOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05392634 | Multicentral Preventive Antibiotics With Cystectomy Within Enhanced Recovery After Surgery(MACS) | unknown | Phase 3 | 98 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 31, 2022 | clinicaltrials |
| NCT04235556 | Integrated Care Pathway in Oncology (PASSION)(PASSION) | unknown | — | 1,800 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 13, 2022 | clinicaltrials |
| NCT05372302 | Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)(CICERONE) | unknown | — | 100 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 12, 2022 | clinicaltrials |
| NCT04718948 | Multimodal Spectroscopy to Detect Urothelial Cancer in Urine | unknown | — | 500 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT04770974 | Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic Characteristic | unknown | — | 200 | University of FlorenceOTHER | 1 | May 9, 2022 | clinicaltrials |
| NCT05154474 | Assessment of Sarcopenia at Diagnosis for Patients With Previously Untreated Metastatic Cancer or Hematologic Malignancy(SPACE2) | unknown | — | 150 | WepromOTHER | 1 | May 3, 2022 | clinicaltrials |
| NCT05344937 | Validation Study of Uromonitor in High Risk Microhematuria Patients | unknown | — | 343 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT02849535 | Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer(PRISM care) | unknown | N/A | 190 | Hospices Civils de LyonOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03062059 | The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | unknown | Phase 2 | 134 | National Cancer Center, KoreaOTHER_GOV | 1 | Apr 14, 2022 | clinicaltrials |
| NCT04784507 | En-Bloc Resection of Bladder Tumors | unknown | Phase 2 | 60 | Betul KartalOTHER | 1 | Apr 12, 2022 | clinicaltrials |
| NCT04339933 | Detection of FGFR Gene Mutations in the Tumor Tissue and Urine of Patients With Urothelial Carcinoma | unknown | — | 92 | Ho Kyung SeoOTHER_GOV | 0 | Apr 7, 2022 | clinicaltrials |
| NCT04876313 | An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Nivolumab and Nab-paclitaxel Before Radical Cystectomy for Patients With Muscle-invasive Bladder Cancer (NURE-Combo)(NURE-Combo) | unknown | Phase 2 | 29 | IRCCS San RaffaeleOTHER | 1 | Apr 6, 2022 | clinicaltrials |
| NCT04602702 | Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors(PDXovo) | unknown | — | 50 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 5, 2022 | clinicaltrials |
| NCT04819399 | Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC | unknown | Phase 1 | 30 | Lindis Biotech GmbHINDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05308771 | To Investigate the Use of a New Syringe "Visual Pressure Control (VPC)" for Epidural Anesthesia in Children Surgery | unknown | N/A | 15 | Centre Hospitalier Universitaire de TivoliOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03759496 | Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer | unknown | Phase 2 | 39 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT03993249 | Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy | unknown | Phase 2 | 78 | Hellenic GenitoUrinary Cancer GroupOTHER | 1 | Mar 23, 2022 | clinicaltrials |
| NCT05077852 | Intravesical Prostatic Protrusion Mimicking Urothelial Cell Carcinoma of the Bladder | unknown | — | 194 | Ankara Training and Research HospitalOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT02994758 | Development of Diagnostics and Treatment of Urological Cancers(DEDUCER) | unknown | N/A | 100 | Helsinki University Central HospitalOTHER | 1 | Mar 11, 2022 | clinicaltrials |
| NCT03762161 | A Phase II Study of Lonsurf (TAS-102) in Metastatic Platinum and Checkpoint Inhibitor-resistant Bladder Cancer | unknown | Phase 2 | 22 | Rahul ParikhOTHER | 1 | Mar 10, 2022 | clinicaltrials |
| NCT02535650 | Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma | unknown | Phase 2 | 19 | Samsung Medical CenterOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT05262166 | Opioid Free Anesthesia in Prolonged Surgery | unknown | N/A | 34 | Mansoura UniversityOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05262413 | A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC) | unknown | Phase 1 / Phase 2 | 60 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Mar 2, 2022 | clinicaltrials |
| NCT03177239 | Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)(UNISoN) | unknown | Phase 2 | 85 | Australian and New Zealand Urogenital and Prostate Cancer Trials GroupOTHER | 1 | Feb 16, 2022 | clinicaltrials |
| NCT05235607 | Personalized Immune Cell Therapy Targeting Neoantigen of Malignant Solid Tumors | unknown | Phase 1 | 60 | Sichuan UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT04638569 | Comparison of Obturator Nerve Block With Ultrasound Guidance and Anatomical Signs | unknown | N/A | 116 | Muğla Sıtkı Koçman UniversityOTHER | 1 | Feb 7, 2022 | clinicaltrials |
| NCT05220124 | A Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma | unknown | Phase 4 | 190 | Tianjin Medical University Second HospitalOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT04603846 | A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma | unknown | Phase 1 | 20 | Lee's Pharmaceutical LimitedINDUSTRY | 1 | Jan 24, 2022 | clinicaltrials |
| NCT02992990 | Bladder Tumor Biopsy Study to Improve Preoperative Determination of Stage and Grade | unknown | N/A | 30 | Baylor College of MedicineOTHER | 1 | Jan 19, 2022 | clinicaltrials |
| NCT05108077 | Treatment of Metastatic Tumors of the Urogenital Area With Cytokine-induced Killer Cells | unknown | Phase 1 / Phase 2 | 20 | Institute of Biophysics and Cell Engineering of National Academy of Sciences of BelarusOTHER_GOV | 1 | Jan 14, 2022 | clinicaltrials |
| NCT03715985 | Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)(NeoPepVac) | unknown | Phase 1 / Phase 2 | 12 | Herlev HospitalOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT05146635 | Optimal Adjuvant Intravesical Therapy for Intermediate Risk Non Muscle Invasive Bladder Cancer: A Randomized Controlled Trial | unknown | N/A | 110 | Mansoura UniversityOTHER | 1 | Jan 11, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Aug 23, 2022source: clinicaltrials